evidence that adenylate kinase, like creatine kinase, is an enzyme that is continuously active.
Both ADP and AMP have been involved in theoretical schemes that would make these compounds instrumental in switching on glycolysis (see Newsholme & Start, 1976; Edstrom et al., 1982) . Clearly such schemes must be incorrect when considered quantitatively. If the change in [ADPI is produced by ischaemia the result is that the muscle becomes alkaline because the stimulation of lactic acid production is both slight and slow (see Fig. 2 ). In very marked contrast, if a similar change in [ADP] is provoked by exercise (Fig. 3) , lactic acid production is so briskly provoked that [H+l increases tenfold within 3 min. Moreover the raised [ADPI (and [AMP] ) do not lead to extra lactic acid production after exercise has ended and before the circulation has been restored.
We are thus lead firmly to the conclusion stated in the first paragraph: lactic acid production is turned on by the events of the contractile cycle, not by changes in the concentrations of the products of metabolism. This conclusion accords with what we have already found in frog muscle (Dawson et al., 1980b, Figs. 7, 8 and 9) and subsequently extended. A more detailed explanation of the work on human subjects is to be found in Dawson (1982) and Wilkie et al. (1983 To define the role of fructose 2,6-bisphosphate in the control of metabolism one should take into consideration its effects in uitro on enzyme activities as well as the factors and conditions which modulate its concentration in tissues. Fructose 2,6-bisphosphate is present in liver, brain, heart, skeletal muscle, adipose tissue, lung and pancreatic islets. Except for the liver and for skeletal muscle, very little if anything is known about conditions inducing changes in the concentration of fructose 2,6-bisphosphate. This article is thus limited to what is known for the liver and skeletal muscle. Fructose 2,6-bisphosphate has been the subject of several recent reviews in which references to the original publications can be found (Hers & Van Schaftingen, 1982; , Hers & Hue, 1983 Pilkis et al., 1982 , Uyeda et al., 1982 .
Control of enzyme actiuiv by fructose 2,6-bisphosphute
Fructose 2,6-bisphosphate is the most potent known stimulator of phosphofructokinase. Its action applies to all mammalian phosphofructokinases so far studied. The kinetic characteristics of liver phosphofructokinase are such that in the presence of physiological concentration of substrates, and particularly ATP, the activity is almost negligible. Fructose 2,6-bisphosphate relieves the inhibition by ATP and allows glycolysis to proceed. It should be noted that the action of fructose 2,6-bisphosphate is remarkably synergistic with that of AMP. Fructose 2,6-bisphosphate is also an inhibitor of fructose 1,6-bisphosphatase. However, it appears thqt in hepatocytes from fed rats containing relatively large concentrations of fructose 2,6-bisphosphate, there is a recycling of metabolites between glucose and triose phosphates indicating that fructose 1,6-bisphosphatase is active. The involvement of fructose 2,6-bisphosphate in the regulation of fructose 1,6-bisphosphatase is therefore difficult to evaluate. In mammalian tissues, the only known effect of fructose 2,dbisphosphate is at the level of phosphofructokinase/fructose 1,6-bisphosphatase and this effect is primarily related to the stimulation of phosphofructokinase. No other effect has been so far described.
Fructose 2,6-bisphosphate is a stimulator of PP, :fructose 6-phosphate phosphotransferase, an enzyme which is present in higher plants; the role of this enzyme in plant metabolism is little understood.
Synthesis and breakdown of fmctose 2,6-bisphosphate
Fructose 2,6-bisphosphate is synthesized from fructose 6-phosphate and ATP by a 6-phosphofructo-2-kinase also called phosphofructokinase 2. It is hydrolysed into fructose 6-phosphate and PI by a phosphatase called fructose 2,6-bisphosphatase. The activity of both enzymes is affected by various metabolites, an important one being fructose 6-phosphate which favours the synthesis of fructose 2,6-bisphosphate and inhibits fructose 2,6-bisphosphatase. Other metabolites such as glycerol 3-phosphate, phosphoenolpyruvate and citrate inhibit phosphofructokinase 2 andlor stimulate fructose 2,6-bisphosphatase. The Vmm, of both enzymes is relatively low (20-6Om-units/g of liver), so that changes in fructose 2,6-bisphosphate concentration require several minutes to become complete. In addition, both enzymes are substrates for the cyclic AMP-dependent protein kinase; phosphorylation of the protein results in an inactivation of phosphofructokinase 2 and an activation of fructose 2,6-bisphosphatase.
It is remarkable that the purification and fractionation procedures have not allowed the separation of phosphofructokinase 2 and fructose 2,6-bisphosphatase. This suggests that the two catalytic properties belong to a single protein.
Control of fructose 2d-bisphosphate concentration
The mechanisms responsible for changes in the concentration of fructose 2,dbisphosphate fall into two groups. The first one corresponds to hormones and agonists.
I n vluo, glucagon causes a fall in the concentration of fructose 2,6-bisphosphate. This is explained by the inactivation of Since the effect of these agents on pyruvate kinase is minimal, they will cause an increase in lactate output. This offers an exdanation in molecular terms for the unexuected stimulatorv Gluconeogenic precursors such as lactate, pyruvate, glycerol and alanine also exert a regulation on fructose 2,6-bisphosphate; they decrease its concentration. This effect is explained by the multimodulation of phosphofructokinase 2 and fructose 2,6-bisphosphatase. These enzyme activities are indeed regulated by a large variety of metabolites such as phosphoenolpyruvate and glycerol 3-phosphate which may signal for the presence of gluconeogenic precursors and prevent the accumulation of fructose 2,6-bisphosphate. By doing so, they will favour gluconeogenesis. Finally, since phosphofructokinase 2 is also inhibited by citrate one may postulate that, in liver oxidizing fatty acids, the concentration of citrate increases and could then cause a fall in fructose 2,6-bisphosphate. It therefore appears that fructose 2,6-bisphosphate is not only a signal for glucose availability but it also integrates information from other substrates and may then influence the limiting step in glycolysis according to the presence of other substrates.
Role of fructose 2,b-bisphosphate
From the above considerations, it appears that the mode of effect of a-adredergic agonists on glycdysis. ' 1 action of fructose 2,6-bisphosphate is to-concentrate information Starvation and diabetes are two conditions in which the ' :
concentration of cyclic AMP in the liver is increased, offering an explanation for the low content in fructose 2,6-bisphosphate, the inhibition of glycolysis and the stimulation of gluconeogenesis. By contrast, in livers from starved genetically obese (oblob) mice the content of fructose 2,6-bisphosphate was 6-fold higher than in starved lean controls. This may contribute to keep an active glycolysis in livers of obese mice and so to provide an increased supply of C, units for lipogenesis, which is known to be increased in the livers of these animals. In skeletal muscle, fructose 2,6-bisphosphate may play a role in the stimulation of glycolysis brought about by adrenalin and insulin.
Besides hormones, other factors influence fructose 2,6-bisphosphate in the liver. Among these, glucose is the most striking one. The stimulation of glycolysis by glucose is best explained by the accumulation of fructose 2,6-bisphosphate which results from an amplification mechanism exerted by phosphofructokinase 2 and fructose 2,6-bisphosphatase on changes in fructose 6-phosphate concentration. This allows phosphofructokinase to work even in the presence of inhibitory concentrations of ATP. By contrast, when glycolysis is maximally stimulated by anoxia, fructose 2,6-bisphosphate concentration falls and cannot therefore be considered as a major control for the onset of glycolysis. One may speculate that a similar regulation exists in muscle during violent anoxic contractions. Indeed, the electrical stimulation of perfused rat hindlimb preparations caused muscukr contraction, a stimulation of lactate production, but decreased the concentration of fructose 2,6-bisphosphate. It therefore appears that the role of fructose 2,6-bisphosphate in the stimulation of glycolysis may be restricted to certain plethoric conditions where it could stimulate glycolysis for anabolic purposes such as lipogenesis. When provision of energy by glycolysis becomes a major issue, fructose 2,6-bisphosphate is probably not the major regulator of phosphofructokinase. Other effectors such as AMP, ATP, P, and citrate may play a role.
from various metabolisms and to express this information at one point of control, namely phosphofructokinase, the limiting step of glycolysis. Although actions of fructose 2,6-bisphosphate on other enzymes are not excluded, the control of phosphofructokinase and fructose 1,6-bisphosphatase is, at the present time, the only known effect of fructose 2,6-bisphosphate.
One may therefore consider that fructose 2,6-bisphosphate behaves as a funnel, an integrator of information which concentrates various inputs on a single point of control. Cyclic AMP has the opposite effect by extending the information from one molecule to various metabolisms. To be efficient, the control by cyclic AMP-dependent hormones should override the control by substrates. As a matter of fact, it appears that the effects of cyclic AMP are superimposed on the regulation by glucose, since cyclic AMP antagonizes the effect of glucose on fructose 2,6-bisphosphate, whereas glucose is unable to reverse directly the effect of cyclic AMP. This difference in behaviour between cyclic AMP and fructose 2,6-bisphosphate is due to the remarkable properties of cyclic AMP-dependent protein kinase (a multisubstrate enzyme) and phosphofructokinase 2/fructose 2,6-bisphosphatase (multimodulated enzymes).
